Clovis Oncology, Inc., a biotech formed by Pharmion execs to develop pancreas and lung cancer drugs, will see its quiet period end on December 26. On November 15, the company raised $130 million by offering 10 million shares at $13, at the low end of the range ...read more
Clovis Oncology, Inc., a biotech formed by Pharmion execs to develop pancreas and lung cancer drugs, raised $130 million by offering 10 million shares at $13. It had originally filed to offer 9.3 million shares at a price range of $13 to $15. Clovis Oncology, ...read more
There are 9 IPOs are expected this week. If all price successfully, it will mark the busiest week since December 2010. Angie's List (ANGI), which operates a subscription-based website used to review local service providers, plans to raise $106 million by...read more
With the Groupon IPO successfully floated and the FTSE Renaissance US IPO Index running ahead of the S&P 500 (+14.5% vs +11.5%, respectively) this quarter, the IPO floodgates have opened as companies rush to get out the door before Thanksgiving. After a two...read more
Clovis Oncology quiet period ends December 26
Clovis Oncology, Inc., a biotech formed by Pharmion execs to develop pancreas and lung cancer drugs, will see its quiet period end on December 26. On November 15, the company raised $130 million by offering 10 million shares at $13, at the low end of the range ...read more
Clovis Oncology prices IPO at $13, at low end of the range
Clovis Oncology, Inc., a biotech formed by Pharmion execs to develop pancreas and lung cancer drugs, raised $130 million by offering 10 million shares at $13. It had originally filed to offer 9.3 million shares at a price range of $13 to $15. Clovis Oncology, ...read more
9 IPOs planned for the week of Nov 14
There are 9 IPOs are expected this week. If all price successfully, it will mark the busiest week since December 2010. Angie's List (ANGI), which operates a subscription-based website used to review local service providers, plans to raise $106 million by...read more
US IPO Calendar erupts, 16 deals set to price in November
With the Groupon IPO successfully floated and the FTSE Renaissance US IPO Index running ahead of the S&P 500 (+14.5% vs +11.5%, respectively) this quarter, the IPO floodgates have opened as companies rush to get out the door before Thanksgiving. After a two...read more